What happened, in summary

Lucy E. was diagnosed with grade 3 triple-negative breast cancer 3 days after her 24th birthday. She had found a breast lump and pushed for biopsy even after being told it was likely fibrous tissue. She already knew she carried a BRCA1 mutation, which made the diagnosis and future family planning more complicated. Treatment moved quickly after the October 13 diagnosis. Before chemotherapy, Lucy completed egg freezing and discussed future embryo testing to avoid passing on the BRCA gene. She also received Zoladex injections during chemotherapy to help protect ovarian function by putting her into temporary medical menopause. Lucy joined a clinical trial. Her main chemotherapy course was carboplatin every 3 weeks plus weekly paclitaxel, with daily olaparib tablets as part of the trial. That phase was planned for 4 cycles / 12 weeks, although low platelets caused a break. She then received EC chemotherapy every 3 weeks for 3 cycles, lasting 9 weeks. Hair loss, fatigue, and treatment side effects were emotionally difficult. On June 17, after chemotherapy, she was told she was all-clear and cancer-free. Surgery still followed. Because of BRCA1 and node involvement, she chose a double mastectomy. Radiotherapy meant the left side could not be reconstructed immediately, so she stayed flat on the left and had a right implant, with DIEP reconstruction planning later. As of January 2023, Lucy was cancer-free and continuing close oncology reviews every 3-4 months.